Mortality increased by 50% in GCA pts compared to matched controls during first year of follow up after dx. Main cause of this early excess mortality appears to be CVD. Abs 0467 #ACR22 @RheumNow https://t.co/TEV0qSlJuQ https://t.co/U8gv2SXhdQ

• All-Cause and Cause-Specific Mortality in Giant Cell Arteritis, a Population-ba…

Death rate is higher in the first year after AAV diagnosis and remains elevated in long-term follow up. Primary cause of death is the vasculitis itself. Abs 0448 #ACR22 @RheumNow https://t.co/z7qBnefTbR https://t.co/PRaUeK2XXd

• All-Cause and Cause-Specific Mortality in ANCA-Associated Vasculitis: A Populat…

@alberta_hoi @RheumNow @seminarthrheum Indeed! Thanks Alberta I think: - they're not as separate as some might think - it's possible beta-blockers could prevent damage-related remodelling - at the least, couldn't they be additive? Whatever the case, if it's real I want to use it. Big signal needs testing? #ACR22

International survey finds induction therapy patterns for severe ANCA-associated vasculitis differ based on physician specialty, expertise, and practice setting. Abs 0442 #ACR22 @RheumNow https://t.co/gB6QhYnbp5 https://t.co/Io2hA9EZiW

• Induction Therapy Patterns for Severe ANCA-associated Vasculitis Differ Based o…

🦵Heel enthesitis on physical exam predictive of ⬇️ likelihood of low disease activity and ⬆️ scores in Global VAS, BASDAI, ASDAS and BASFI on 2yr follow up in r-axSpA # The Achilles heel of r-axSpA! Abst#0375 #ACR22 @RheumNow

@rheum_cat et al Abs 0415 TNFi initiation early in AS dz course (compared to no initiation) showed higher risk of incident CVD, stroke & MACE individually! Residual confounding by indication cannot be excluded. Were TNFi tx pts sicker? #ACR22 @RheumNow https://t.co/ERoDhS2yOY https://t.co/8tto5AIUSP

• The Association of Early TNF Inhibitor Use with Incident Cardiovascular Events …

🤕 Late onset PsA associated with ⬆️ structural damage 💪🏻UL > LL arthritis ⬆️ BASFI 🙋‍♂️ males ⬇️ enthesitis/ sacroilitis Abst# 0377 #ACR22 @RheumNow

Can I use BASDAI to asses disease in #pregnant AS patients? Abstract #0374 #ACR22 @RheumNow; 50 women 🫃Back pain and fatigue beyond 4.5 months = not reliable 🫃BASDAI in 3rd trimester = not reliable 🫃Morning stiffness remains reliable marker of disease in pregnancy

Abs 0478 at #ACR22 study indicates that a single screening US of temporal and axillary arteries accurately identified 83.3% of patients with subclinical GCA in an inception PMR cohort. It may not change tx but possibly timeline for tx, IMO. @RheumNow https://t.co/bEBVfxDNir https://t.co/UQ1EdniGk5

• Sonographic Prevalence of Subclinical GCA in Newly Diagnosed PMR - ACR Meeting …

Wanna know more about SpA in female patients? Just ask @Sineadm15! Check out my interview with her at #ACR22 @RheumNow https://t.co/NSM4pJeb6g

• Do Disease Activity Measures Really Capture AS in Women? | RheumNow

👁 What causes worse outcomes in our SpA uveitis pts? 👁 🚬 smoking Hx 🦴 ax + peripheral disease ✏️ BASDAI >4 👩‍🔬 HLA B27 +ve 🙋‍♀️ females 🧪CRP ⬆️ 👁 bilat eye involvement Abst#0373 #ACR22 @RheumNow

IL-17A/F inhibition with Bimekizumab in active nr-axSpA Wk 16 ASAS40 vs PBO • Rapid improvement 47.7 vs 21.4% • TNF naive 46.6 vs 22.9% • TNFIR 60 vs 11.8% • Wk 24 >50% ASDAS <2.1 • Improved MRI • Serious TEAE 0.4% Deodhar Abs0544 https://t.co/q9dbQP5oLD #ACR22 @RheumNow https://t.co/VCJgo56JrA

• Bimekizumab Improves Signs and Symptoms, Including Inflammation, in Patients wi…

QD Clinic - How to Treat Erosive OA (abstract #L05) 61yoWM with bilateral pain/swelling in DIPs. Labs normal, seronegative and Xrays shows evidence of DIP erosive OA. But what works in EOA? #ACR22 https://t.co/tbIoTg6kxA https://t.co/YcW7TON0En

• https://bit.ly/3hu88u6